Jeffrey Levenson, MD
Ophthalmology · Jacksonville, FLNPI 1023118379
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.5%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 33.8% of the total. Reporting peaked in 2023 at $6,576 and has fallen 80.1% since, to $1,307 in 2025. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 280 payments — averaging $58.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$6K
- AbbVie$4K
- GSK$2K
- Alcon$1K
- Glaukos Corporation$491
- Sight Sciences, Inc.$472
- plus $3K from 29 others
Across 365 payments — averaging $4778.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1.1M
- Johnson & Johnson Surgical Vision, Inc.$364K
- Glaukos Corporation$139K
- Alcon Research LLC$52K
- Bausch Health US, LLC$34K
- Amgen$24K
- plus $12K from 2 others
What the payments were for
- Consulting fees$8,87555%
- Speaking & faculty fees$1001%
- Food & beverage$7,27645%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 12 | $5,506 |
| AbbVie(2 entities) | 87 | $3,566 |
| GSK | 3 | $1,980 |
| Alcon | 33 | $1,040 |
| Glaukos Corporation | 16 | $491 |
| Sight Sciences, Inc. | 16 | $472 |
| Kala Pharmaceuticals, Inc. | 5 | $352 |
| Bausch & Lomb Americas Inc. | 15 | $293 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $290 |
| Aerie Pharmaceuticals, Inc. | 6 | $250 |
| Biotissue Holdings Inc. | 6 | $242 |
| Amgen(2 entities) | 8 | $220 |
| Harrow Eye, LLC | 8 | $186 |
| Tarsus Pharmaceuticals, Inc. | 6 | $185 |
| Sun Pharmaceutical Industries Inc. | 6 | $157 |
| Astellas Pharma US Inc | 2 | $134 |
| Argenx US, Inc. | 1 | $111 |
| Rayner Intraocular Lenses Limited | 5 | $109 |
| Novartis | 5 | $108 |
| Mallinckrodt Hospital Products Inc. | 5 | $96 |
| Gilead | 3 | $90 |
| Carl Zeiss Meditec USA, Inc. | 1 | $43 |
| Halozyme Inc | 1 | $39 |
| Oyster Point Pharma, Inc. | 2 | $37 |
| Ivantis, Inc | 2 | $36 |
| NEW World Medical,inc. | 6 | $35 |
| Johnson & Johnson | 2 | $34 |
| Shire North American Group Inc | 2 | $34 |
| Dompe US, Inc. | 2 | $33 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Omeros Corporation | 1 | $19 |
| Ocular Therapeutix, Inc. | 1 | $18 |
| Thea Pharma Inc. | 1 | $16 |
| Eyevance Pharmaceuticals LLC | 1 | $16 |
| Eyepoint US, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis Simplicity$5,000
- XEN GLAUCOMA TREATMENT SYSTEM$2,141
- BLENREP$1,950
- Rocklatan$353
- OMNI(R) SURGICAL SYSTEM (US)$259
- Rhopressa$232
- INVELTYS$196
- NGENUITY$144
- Luxor$144
- ReSTOR$131
- Tecnis Multifocal Family of 1-piece IOLS$125
- Clareon$114
- TEPEZZA$107
- Tecnis iTec Preloaded Delivery System$104
- EYSUVIS$102
- DURYSTA$102
- VYZULTA$101
- XEN$100
How this compares
$16,271 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 455 | $215,602 |
| RestasisCyclosporine | 165 | $199,116 |
| RocklatanNetarsudil Mesylat/Latanoprost | 124 | $61,026 |
| CombiganBrimonidine Tartrate/Timolol | 126 | $56,106 |
| Prednisolone Acetate | 1,116 | $55,109 |
| Latanoprost | 3,119 | $41,146 |
| RhopressaNetarsudil Mesylate | 71 | $34,378 |
| XiidraLifitegrast | 34 | $33,682 |
| Alphagan PBrimonidine Tartrate | 64 | $27,335 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 99 | $25,267 |
| VyzultaLatanoprostene Bunod | 59 | $22,927 |
| Cyclosporine | 36 | $20,499 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 116 | $19,935 |
| Ketorolac Tromethamine | 846 | $18,674 |
| Travoprost | 124 | $17,840 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $3,566 | $498,159810 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $250 | $95,404195 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $293 | $56,60893 claims |
| AlconSimbrinza | $1,040 | $25,26799 claims |
| Eyevance Pharmaceuticals LLCFlarex | $16 | $1,69712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Jacksonville
- Syril DorairajJacksonville$432K
- Frank BowdenJacksonville$169K
- David KostickJacksonville$108K
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.